Calliditas Therapeutics Clocked Preliminary Net TARPEYO Revenues of $31M–$33M in Q4, FY23 Preliminary Net TARPEYO Revenues of $100M–$102M, up 170% YoY, FY23 Preliminary Total revenues of $110M–$113M

Author: Benzinga Newsdesk | January 08, 2024 03:41am

Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today provided a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financial information for the fourth quarter and full year 2023, as follows:

• Strong Q4 preliminary product revenue growth with net TARPEYO revenues of $31 – 33m for the quarter, representing significant growth over Q3.
• Preliminary Net TARPEYO revenues of $100 – 102m for 2023, representing over 170% year over year growth compared to 2022.
• Preliminary Total revenues reaching $110 – 113m for 2023, as a result of milestone payments and royalty income from the Nefecon franchise outside the US.  
• Record quarter in terms of enrollments with 555 new TARPEYO prescriptions in the 4th quarter.

The information above reflects our preliminary estimates with respect to such results based on currently available information. We have provided ranges, rather than specific amounts, for the preliminary results described above primarily because our financial closing procedures are not yet complete and, as a result, our final results may vary from the preliminary estimates.

Posted In: CALT